2. Academic Validation
  3. Synthesis and preclinical evaluation of 2-(2-furanyl)-7-[2-[4-[4-(2-[11C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine ([11C]Preladenant) as a PET tracer for the imaging of cerebral adenosine A2A receptors

Synthesis and preclinical evaluation of 2-(2-furanyl)-7-[2-[4-[4-(2-[11C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine ([11C]Preladenant) as a PET tracer for the imaging of cerebral adenosine A2A receptors

  • J Med Chem. 2014 Nov 13;57(21):9204-10. doi: 10.1021/jm501065t.
Xiaoyun Zhou 1,  Shivashankar Khanapur,  Anja P Huizing,  Rolf Zijlma,  Marianne Schepers,  Rudi A J O Dierckx,  Aren van Waarde,  Erik F J de Vries,  Philip H Elsinga
Affiliations

Affiliation

  • 1 Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen , Hanzeplein 1, 9713GZ Groningen, The Netherlands.
PMID: 25279444 DOI: 10.1021/jm501065t
Abstract

2-(2-Furanyl)-7-[2-[4-[4-(2-[(11)C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine-5-amine [(11)C]-3 ([(11)C]Preladenant) was developed for mapping cerebral adenosine A2A receptors (A2ARs) with PET. The tracer was synthesized in high specific activity and purity. Tissue distribution was studied by PET imaging, ex vivo biodistribution (BD), and in vitro autoradiography (ARG) experiments. Regional brain uptake of [(11)C]-3 was consistent with known A2ARs distribution, with highest uptake in striatum. The results indicate that [(11)C]-3 has favorable brain kinetics and exhibits suitable characteristics as an A2AR PET tracer.

Figures
Products